Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics (NASDAQ: GALT) reported financial results for Q2 2024 and provided a business update. Key highlights include:
1. The NAVIGATE Phase 2b/3 trial of belapectin for MASH cirrhosis is on track for interim top-line analysis in December 2024.
2. Presented data at EASL 2024 showing no correlation between collagen content in liver biopsies and portal pressure in MASH cirrhotic patients.
3. As of June 30, 2024, the company had $25.6 million in cash and cash equivalents, with an additional $10 million available under a line of credit.
4. Q2 2024 net loss was $12.4 million ($0.20 per share), compared to $9.2 million ($0.15 per share) in Q2 2023.
5. Research and development expenses increased to $9.8 million in Q2 2024 from $7.4 million in Q2 2023.
Galectin Therapeutics (NASDAQ: GALT) ha riportato i risultati finanziari per il secondo trimestre del 2024 e fornito un aggiornamento aziendale. I punti salienti includono:
1. Lo studio NAVIGATE di fase 2b/3 su belapectin per la cirrosi MASH è programmato per un'analisi provvisoria dei risultati nel dicembre 2024.
2. Dati presentati all'EASL 2024 mostrano che non c'è correlazione tra il contenuto di collagene nelle biopsie epatiche e la pressione portale nei pazienti cirrotici con MASH.
3. Alla data del 30 giugno 2024, l'azienda disponeva di 25,6 milioni di dollari in cassa e equivalenti, con ulteriori 10 milioni disponibili tramite una linea di credito.
4. La perdita netta del secondo trimestre 2024 è stata di 12,4 milioni di dollari (0,20 dollari per azione), rispetto a 9,2 milioni di dollari (0,15 dollari per azione) nel secondo trimestre 2023.
5. Le spese per ricerca e sviluppo sono aumentate a 9,8 milioni di dollari nel secondo trimestre 2024, rispetto a 7,4 milioni di dollari nel secondo trimestre 2023.
Galectin Therapeutics (NASDAQ: GALT) reportó los resultados financieros del segundo trimestre de 2024 y ofreció una actualización de negocios. Los aspectos más destacados incluyen:
1. El ensayo NAVIGATE de fase 2b/3 de belapectin para la cirrosis MASH está programado para un análisis interino en diciembre de 2024.
2. Se presentaron datos en EASL 2024 que muestran que no hay correlación entre el contenido de colágeno en las biopsias hepáticas y la presión portal en los pacientes cirróticos con MASH.
3. A fecha del 30 de junio de 2024, la compañía tenía 25,6 millones de dólares en efectivo y equivalentes, con otros 10 millones disponibles bajo una línea de crédito.
4. La pérdida neta del segundo trimestre de 2024 fue de 12,4 millones de dólares (0,20 dólares por acción), en comparación con 9,2 millones de dólares (0,15 dólares por acción) en el segundo trimestre de 2023.
5. Los gastos en investigación y desarrollo aumentaron a 9,8 millones de dólares en el segundo trimestre de 2024 desde 7,4 millones de dólares en el segundo trimestre de 2023.
갈렉틴 테라퓨틱스 (NASDAQ: GALT)는 2024년 2분기 재무 결과를 보고하고 사업 업데이트를 제공했습니다. 주요 사항은 다음과 같습니다:
1. MASH 간경변에 대한 belapectin의 NAVIGATE 2b/3 임상 시험은 2024년 12월 중간 결과 분석을 예정하고 있습니다.
2. EASL 2024에서 발표된 데이터는 MASH 간경변 환자의 간 생검에서 콜라겐 양과 문맥압 간에 상관관계가 없음을 보여줍니다.
3. 2024년 6월 30일 기준, 회사는 2,560만 달러의 현금 및 현금성 자산을 보유하고 있으며, 추가로 1,000만 달러를 신용 한도에 따라 사용할 수 있습니다.
4. 2024년 2분기 순손실은 1,240만 달러 (주당 0.20 달러)로, 2023년 2분기의 920만 달러 (주당 0.15 달러)에 비해 증가했습니다.
5. 2024년 2분기 연구개발비는 2023년 2분기의 740만 달러에서 980만 달러로 증가했습니다.
Galectin Therapeutics (NASDAQ: GALT) a présenté les résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour sur ses activités. Les principaux points à retenir incluent :
1. L'essai NAVIGATE de phase 2b/3 sur belapectin pour la cirrhose MASH est sur la bonne voie pour une analyse intérimaire des résultats en décembre 2024.
2. Des données présentées lors de l'EASL 2024 montrent qu'il n'y a aucune corrélation entre la teneur en collagène dans les biopsies hépatiques et la pression portale chez les patients atteints de cirrhose MASH.
3. Au 30 juin 2024, la société avait 25,6 millions de dollars en liquidités et équivalents, avec 10 millions de dollars supplémentaires disponibles dans le cadre d'une ligne de crédit.
4. La perte nette du deuxième trimestre 2024 était de 12,4 millions de dollars (0,20 dollar par action), comparativement à 9,2 millions de dollars (0,15 dollar par action) au deuxième trimestre 2023.
5. Les dépenses en recherche et développement ont augmenté à 9,8 millions de dollars au deuxième trimestre 2024, contre 7,4 millions de dollars au deuxième trimestre 2023.
Galectin Therapeutics (NASDAQ: GALT) hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und ein Update zum Geschäft gegeben. Die wichtigsten Highlights sind:
1. Die NAVIGATE Phase 2b/3 Studie zu belapectin bei MASH-Zirrhose ist auf Kurs für eine vorläufige Analyse der Hauptdaten im Dezember 2024.
2. Präsentierte Daten auf dem EASL 2024 zeigen keine Korrelation zwischen dem Kollagengehalt in Leberbiopsien und dem portalen Druck bei MASH-zirrhotischen Patienten.
3. Zum 30. Juni 2024 verfügte das Unternehmen über 25,6 Millionen Dollar in Bargeld und Zahlungsmitteln sowie zusätzlich 10 Millionen Dollar, die über eine Kreditlinie verfügbar sind.
4. Der Nettoverlust im zweiten Quartal 2024 betrug 12,4 Millionen Dollar (0,20 Dollar pro Aktie), im Vergleich zu 9,2 Millionen Dollar (0,15 Dollar pro Aktie) im zweiten Quartal 2023.
5. Die Forschungs- und Entwicklungskosten stiegen im zweiten Quartal 2024 auf 9,8 Millionen Dollar, gegenüber 7,4 Millionen Dollar im zweiten Quartal 2023.
- NAVIGATE Phase 2b/3 trial of belapectin progressing as planned with interim top-line data expected in December 2024
- Presented important data at EASL 2024 Congress highlighting the effectiveness of endoscopies in assessing MASH cirrhosis progression
- $10 million remaining available under a line of credit to fund operations
- Net loss increased to $12.4 million in Q2 2024 from $9.2 million in Q2 2023
- Research and development expenses increased to $9.8 million in Q2 2024 from $7.4 million in Q2 2023
- Current cash expected to fund operations only through May 15, 2025
Galectin Therapeutics' Q2 2024 results reveal a mixed financial picture. The company's cash position of
The NAVIGATE trial for belapectin in MASH cirrhosis is progressing as planned, with a critical interim analysis expected in December 2024. This could be a pivotal moment for Galectin Therapeutics. The recent EASL 2024 poster presentation revealed an important finding: collagen content in liver biopsies doesn't correlate with portal pressure in MASH cirrhotic patients. This underscores the significance of endoscopies in assessing esophageal varices development. If belapectin proves effective in preventing these varices, it could address a significant unmet medical need in MASH-associated liver cirrhosis, potentially opening a substantial market opportunity for Galectin Therapeutics.
- NAVIGATE trial on track for interim top-line analysis in December 2024
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024.
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said, “We continued to advance the NAVIGATE Phase 2b/3 trial of belapectin in the first half of 2024. We believe that belapectin can potentially offer a new medical treatment option for the increasing number of patients affected with MASH associated liver cirrhosis and portal hypertension that represents a significant unmet medical need, and we are excited for the planned upcoming interim analysis in December 2024.”
Khurram Jamil, M.D., Chief Medical Officer, added, “We were pleased to share the important data from our belapectin program demonstrating that collagen content in liver biopsies of MASH cirrhotic patients does not correlate with portal pressure, which is a key marker of disease progression at the EASL 2024 congress. These insights underscore the importance of truly understanding the overall health of the liver and highlights the effectiveness of endoscopies in determining that.”
Belapectin Program Q2 2024 and Recent Highlights
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis.
MASH Cirrhosis
- The NAVIGATE Phase 2b/3 trial (NCT04365868) evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in MASH in 357 patients across 14 countries on five continents is progressing as planned. Interim top-line data readout from the Phase 2b portion of the trial is anticipated late in December 2024.
- Presented a poster at the European Association for the Study of the Liver (EASL) 2024 Congress. The poster highlighted data from an evaluation of the correlation between portal pressure, collagen proportional area, and α-smooth muscle actin in patients with portal hypertension due to MASH cirrhosis. The data showed that collagen content in liver biopsies of MASH cirrhotic patients fails to correlate with measures of portal pressure, a main marker of disease progression and underscores the importance of endoscopies to assess the development of esophageal varices, a direct consequence of increased portal pressure.
Q2 2024 Financial Highlights
- As of June 30, 2024, the Company had
$25.6 million of cash and cash equivalents. Additionally, the Company has$10 million remaining available under a line of credit provided by its chairman of the board to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through approximately May 15, 2025. - Research and development expenses for the quarter ended June 30, 2024 were
$9.8 million compared with$7.4 million for the same period in 2023. The increase was primarily due to timing of incurrence of expenditures related to our NAVIGATE clinical trial. - General and administrative expenses for the quarter ended June 30, 2024 were
$1.5 million , compared to$1.6 million for the quarter ended June 30, 2023. - For the quarter ended June 30, 2024, the Company reported a net loss applicable to common stockholders of
$12.4 million , or ($0.20) per share, compared to a net loss applicable to common stockholders of$9.2 million , or ($0.15) per share for the quarter ended June 30, 2023. - These results are included in the Company's Quarterly Report on Form 10-Q as of and for the period ended June 30, 2024, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect,” “look forward,” “believe,” “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
Condensed Consolidated Statements of Operations
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| (in thousands, except per share data) | ||||||||||||
| Operating expenses: | ||||||||||||
| Research and development | $ | 9,813 | $ | 7,371 | $ | 17,867 | $ | 16,170 | ||||
| General and administrative | 1,478 | 1,632 | 3,072 | 3,175 | ||||||||
| Total operating expenses | 11,291 | 9,003 | 20,939 | 19,345 | ||||||||
| Total operating loss | (11,291) | (9,003) | (20,939) | (19,345) | ||||||||
| Other income (expense): | ||||||||||||
| Interest income | 80 | 50 | 160 | 93 | ||||||||
| Interest expense | (1,269) | (650) | (2,321) | (1,110) | ||||||||
| Change in fair value of derivative | 109 | 489 | (760) | (279) | ||||||||
| Total other income | (1,080) | (111) | (2,921) | (1,296) | ||||||||
| Net loss | $ | (12,371) | $ | (9,114) | $ | (23,860) | $ | (20,641) | ||||
| Preferred stock dividends | (64) | (63) | (72) | (63) | ||||||||
| Warrant modification | ||||||||||||
| Net loss applicable to common stock | $ | (12,435) | $ | (9,177) | $ | (23,932) | $ | (20,704) | ||||
| Basic and diluted net loss per share | $ | (0.20) | $ | (0.15) | $ | (0.38) | $ | (0.35) | ||||
| Shares used in computing basic and diluted net loss per share | 62,233 | 59,582 | 62,192 | 59,531 | ||||||||
Condensed Consolidated Balance Sheet Data
| June 30, 2024 | December 31, 2023 | |||||
| (in thousands) | ||||||
| Cash and cash equivalents | $ | 25,598 | $ | 25,660 | ||
| Total assets | 27,655 | 28,200 | ||||
| Total current liabilities | 14,617 | 15,676 | ||||
| Total liabilities | 109,802 | 88,441 | ||||
| Total redeemable, convertible preferred stock | 1,723 | 1,723 | ||||
| Total stockholders’ equity (deficit) | $ | (83,870) | $ | (61,964) | ||
FAQ
When is the interim top-line data readout expected for Galectin Therapeutics' (GALT) NAVIGATE trial?
What was Galectin Therapeutics' (GALT) net loss for Q2 2024?
How much cash does Galectin Therapeutics (GALT) have as of June 30, 2024?
What is the focus of Galectin Therapeutics' (GALT) NAVIGATE trial?
